/LIDDS.ST
LIDDS.ST Stock - LIDDS AB (publ)
Healthcare|BiotechnologySTO
$0.04-29.44%
$0.01 (-29.44%) • Dec 23
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.04
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LIDDS.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.03 – $0.04
TARGET (TP)$0.04
STOP LOSS$0.03
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.05
52W High$0.23
52W Low$0.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $32,000 | N/A | $1.89M | $3.55M | $345,000 |
| Gross Profit | $-3,405,000 | $-12,922,000 | $-36,620,000 | $-25,781,000 | $-24,789,000 |
| Gross Margin | -10640.6% | N/A | -1939.6% | -725.4% | -7185.2% |
| Operating Income | $-6,862,000 | $-40,674,000 | $-36,617,000 | $-37,269,000 | $-32,326,000 |
| Net Income | $-5,938,000 | $-40,206,000 | $-36,860,000 | $-37,270,000 | $-32,334,000 |
| Net Margin | -18556.3% | N/A | -1952.3% | -1048.7% | -9372.2% |
| EPS | $-0.04 | $-0.63 | $-1.07 | $-1.08 | $-1.12 |
Company Overview
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LIDDS.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 27, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q4 2025 | Nov 20, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 28, 2025 | — | $-0.01 | — | — |
Q2 2025 | May 28, 2025 | — | $-0.01 | — | — |
Q1 2025 | Feb 20, 2025 | — | $-0.01 | — | — |
Q4 2024 | Nov 21, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 28, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.01 | — | — |
Q1 2024 | Feb 22, 2024 | — | $-0.27 | — | — |
Q4 2023 | Nov 28, 2023 | — | $-0.07 | — | — |
Q3 2023 | Aug 31, 2023 | — | $-0.11 | — | — |
Q2 2023 | May 29, 2023 | — | $-0.18 | — | — |
Q1 2023 | Mar 13, 2023 | — | $-0.25 | — | — |
Q4 2022 | Nov 28, 2022 | — | $-0.22 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-0.27 | — | — |
Q2 2022 | May 24, 2022 | — | $-0.27 | — | — |
Q1 2022 | Feb 23, 2022 | — | $-0.22 | — | — |
Q4 2021 | Nov 22, 2021 | — | $-0.24 | — | — |
Q3 2021 | Aug 26, 2021 | — | $-0.30 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LIDDS.ST
What is LIDDS.ST's current stock price?
LIDDS AB (publ) (LIDDS.ST) is currently trading at $0.04 per share. The stock has moved -29.44% today.
What is the analyst price target for LIDDS.ST?
No analyst price targets are currently available for this stock.
What sector is LIDDS AB (publ) in?
LIDDS AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is LIDDS.ST's market cap?
LIDDS AB (publ) has a market capitalization of $0.00 billion, making it a small-cap company.
Does LIDDS.ST pay dividends?
No, LIDDS AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector2CUREX.ST
2cureX AB (publ)
$0.75
Mkt Cap: $0.0B
APTA.ST
Aptahem AB (publ)
$1.12
Mkt Cap: $0.0B
CMH.ST
Chordate Medical Holding AB (publ)
$0.61
Mkt Cap: $0.0B
FLUI.ST
Fluicell AB (publ)
$11.30
Mkt Cap: $0.0B
GABA.ST
Gabather AB (publ)
$0.03
Mkt Cap: $0.0B
GUARD.ST
Guard Therapeutics International AB (publ)
$1.40
Mkt Cap: $0.0B
PLUN.ST
ProstaLund AB (publ)
$0.21
Mkt Cap: $0.0B
QUIA.ST
Quia Pharma AB (publ)
$0.00
Mkt Cap: $0.0B
S2M.ST
S2Medical AB (publ)
$0.01
Mkt Cap: $0.0B
STABL.ST
Stayble Therapeutics AB (publ)
$0.21
Mkt Cap: $0.0B
Explore stocks similar to LIDDS.ST for comparison